Brokerages remain bullish on select large- and mid-cap stocks, citing strong earnings visibility and long-term growth drivers ...
Japan’s MHLW grants Pioneering Regenerative Medical Product designation to BlueRock Therapeutics’ investigative cell therapy, bemdaneprocel for treating Parkinson’s disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback